Category: St. Jude MedicalSyndicate content

Report: New tax hasn't hurt medtech R&D | MassDevice.com On Call

May 23, 2014 by Arezu Sarvestani

A look at some of the top medical device companies suggests that the long-lamented medical device tax hasn't had much of an impact on their research & development budgets.

MassDevice.com On Call

MASSDEVICE ON CALL — Despite repeated warnings and laments, the medical device tax implemented with healthcare reform hasn't appeared to make much of a dent in the industry's research & development activities, according to a small report.

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

May 22, 2014 by Arezu Sarvestani

St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.

EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash

Abbott to expand medical device footprint? | Medtech Wall Street news for the week of May 12, 2014

May 15, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott may look to expand medical device business footprint; Device makers take big writedowns on renal denervation; Cardinal Health closes $320M AccessClosure buy; K2M prices IPO under range at $132M; Allergan board spurns Valeant's $47B offer.

Abbott may look to expand medical device business footprint

May 9, 2014 by Brad Perriello

Abbott may look to expand medical device business footprint

TAVI: St. Jude implants 1st patients in U.S. Portico study

May 14, 2014 by Arezu Sarvestani

St. Jude Medical launches a U.S. study of its Portico transcatheter aortic valve in patients who are not candidates for open heart surgery.

St. Jude implants 1st patient in U.S. Portico study

Minnesota medtech maker St. Jude Medical (NYSE:STJ) launched a U.S. study of its Portico catheter-based aortic valve, enrolling the 1st patients in pursuit of FDA approval for the implant.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Device makers take big writedowns on renal denervation

May 13, 2014 by Brad Perriello

Boston Scientific, Medtronic and Covidien take millions in write-downs on their renal denervation assets after the failure of Medtronic's Symplicity-3 trial.

Device makers take big writedowns on renal denervation

HRS2014: Perforations, deaths temporarily derail St. Jude's E.U. Nanostim study

May 12, 2014 by Arezu Sarvestani

Two perforation-related deaths and 4 additional adverse events temporarily derail enrollment in St. Jude Medical's European Nanostim registry as the company evaluates the patient injuries.

Updated May 12, 2014, at 5:30 p.m. with confirmation from St. Jude Medical.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

HRS2014 wrap-up: Medtronic delays ICD therapy, Boston Scientific watches patients from afar, and more

May 12, 2014 by Arezu Sarvestani

Medtech's biggest players release a slew of new reports at this year's Heart Rhythm Society conference, with Medtronic data on preventive shocks for ICD patients, lowered mortality for patients remotely monitored with Boston Scientific's LATITUDE system, and more.

HRS2014 wrap-up: Medtronic delays ICD therapy, Boston Scientific watches patients from afar, and more

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp